Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study).
Matthias AugustinRachel SommerEsteban DaudénPhilip LawsElke de JongGabriella FabbrociniLuigi NaldiAlexander NavariniJo LambertZiad ReguiaiSascha GerdesEric MassanaTeresa ObisIsmail KasujeeUlrich MrowietzPublished in: BMJ open (2023)
ClinicalTrials.gov Identifier: NCT04823247 (Pre-results).